Drug Profile
Research programme: cystathionine gamma-lyase inhibitors - Sova Pharmaceuticals
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Sova Pharmaceuticals
- Class
- Mechanism of Action Cystathionine gamma-lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory pain; Neuropathic pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammatory-pain in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in USA